Fu Changfang, Wang Gang, Yang Wulin
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, People's Republic of China.
Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, People's Republic of China.
Cancer Manag Res. 2021 Nov 25;13:8849-8853. doi: 10.2147/CMAR.S338023. eCollection 2021.
Immune checkpoint inhibitors may cause unique immune-related adverse events. Vascular thrombosis, especially arterial thrombosis, is rare but life-threatening, and little is known about its relevance to immunotherapy. Here, we reported two cases of vascular thrombosis, including venous and arterial thrombosis in cancer patients receiving anti-PD-1 antibody in combination with chemotherapy. Systemic corticosteroids and anticoagulant treatment were administered immediately in two cases. In case 1, anti-PD-1 antibody was permanently discontinued, and recurrence of vascular thrombosis was not observed during the follow-up. In case 2, the patient continued anti-PD-1 immunotherapy and unfortunately died of cerebral infarction 2 months later. This case report provides a strong evidence for the association between PD-1 blockade and vascular thrombosis and offers some general guidelines on the management of the immune-related vascular thrombosis events induced by anti-PD-1 therapy.
免疫检查点抑制剂可能会引发独特的免疫相关不良事件。血管血栓形成,尤其是动脉血栓形成,虽罕见但危及生命,而关于其与免疫治疗的相关性却知之甚少。在此,我们报告了两例血管血栓形成病例,包括接受抗PD - 1抗体联合化疗的癌症患者发生的静脉和动脉血栓形成。两例均立即给予全身性皮质类固醇和抗凝治疗。病例1中,抗PD - 1抗体被永久停用,随访期间未观察到血管血栓形成复发。病例2中,患者继续接受抗PD - 1免疫治疗,不幸的是2个月后死于脑梗死。本病例报告为PD - 1阻断与血管血栓形成之间的关联提供了有力证据,并为抗PD - 1治疗引起的免疫相关血管血栓形成事件的管理提供了一些通用指南。